Mutational re-modeling of di-aspartyl intramembrane proteases: uncoupling physiologically-relevant activities from those associated with Alzheimer\u27s disease by Grigorenko, Anastasia P. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2017-05-30 
Mutational re-modeling of di-aspartyl intramembrane proteases: 
uncoupling physiologically-relevant activities from those 
associated with Alzheimer's disease 
Anastasia P. Grigorenko 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Biochemistry, Biophysics, and Structural Biology Commons, Cellular and Molecular 
Physiology Commons, Mental Disorders Commons, Molecular and Cellular Neuroscience Commons, and 
the Nervous System Diseases Commons 
Repository Citation 
Grigorenko AP, Moliaka YK, Plotnikova OV, Smirnov A, Nikishina VA, Goltsov AY, Gusev F, Andreeva TV, 
Nelson O, Bezprozvanny I, Rogaev EI. (2017). Mutational re-modeling of di-aspartyl intramembrane 
proteases: uncoupling physiologically-relevant activities from those associated with Alzheimer's disease. 
Open Access Articles. https://doi.org/10.18632/oncotarget.18299. Retrieved from 
https://escholarship.umassmed.edu/oapubs/3282 
Creative Commons License 
This work is licensed under a Creative Commons Attribution 3.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Oncotarget82006www.impactjournals.com/oncotarget
Mutational re-modeling of di-aspartyl intramembrane proteases: 
uncoupling physiologically-relevant activities from those 
associated with Alzheimer’s disease
Anastasia P. Grigorenko1,2,3,*, Youri K. Moliaka1,*, Olga V. Plotnikova1, Alexander 
Smirnov1, Vera A. Nikishina1, Andrey Y. Goltsov2,3, Fedor Gusev2,3, Tatiana V. 
Andreeva2,3, Omar Nelson4, Ilya Bezprozvanny4 and Evgeny I. Rogaev1,2,3,5
1Department of Psychiatry, Brudnick Neuropsychiatric Research Institute, University of Massachusetts Medical School, 
Worcester, MA 01604, USA
2Department of Genomics and Human Genetics, Institute of General Genetics, Russian Academy of Sciences, Moscow, 
119991 Russia
3Center for Brain Neurobiology and Neurogenetics, Institute of Cytology and Genetics, Siberian Branch of the Russian 
Academy of Sciences, Novosibirsk, 630090, Russia
4Department of Physiology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9040, USA
5Center for Genetics and Genetic Technologies, Faculty of Biology, Faculty of Bioengineering and Bioinformatics, Lomonosov 
Moscow State University, Moscow, 119234, Russia
*These authors have contributed equally to this work
Correspondence to: Anastasia P. Grigorenko, email: Anastasia.Grigorenko@umassmed.edu
Evgeny I. Rogaev, email: Evgeny.Rogaev@umassmed.edu
Keywords: regulated intramembrane proteolysis, intramembrane aspartyl proteases, presenilin, IMPAS/SPP, mutational re-modelling
Received: October 04, 2016     Accepted: April 28, 2017     Published: May 30, 2017
Copyright: Grigorenko et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
The intramembrane proteolytic activities of presenilins (PSEN1/PS1 and PSEN2/
PS2) underlie production of β-amyloid, the key process in Alzheimer’s disease (AD). 
Dysregulation of presenilin-mediated signaling is linked to cancers. Inhibition of the 
γ-cleavage activities of PSENs that produce Aβ, but not the ε-like cleavage activity that 
release physiologically essential transcription activators, is a potential approach for 
the development of rational therapies for AD. In order to identify whether different 
activities of PSEN1 can be dissociated, we designed multiple mutations in the 
evolutionary conserved sites of PSEN1. We tested them in vitro and in vivo assays and 
compared their activities with mutant isoforms of presenilin-related intramembrane 
di-aspartyl protease (IMPAS1 (IMP1)/signal peptide peptidase (SPP)). PSEN1 auto-
cleavage was more resistant to the mutation remodeling than the ε-like proteolysis. 
PSEN1 with a G382A or a P433A mutation in evolutionary invariant sites retains 
functionally important APP ε- and Notch S3- cleavage activities, but G382A inhibits 
APP γ-cleavage and Aβ production and a P433A elevates Aβ. The G382A variant cannot 
restore the normal cellular ER Ca2+ leak in PSEN1/PSEN2 double knockout cells, but 
efficiently rescues the loss-of-function (Egl) phenotype of presenilin in C. elegans. 
We found that, unlike in PSEN1 knockout cells, endoplasmic reticulum (ER) Ca2+ leak 
is not changed in the absence of IMP1/SPP. IMP1/SPP with the analogous mutations 
retained efficiency in cleavage of transmembrane substrates and rescued the lethality 
of Ce-imp-2 knockouts. In summary, our data show that mutations near the active 
catalytic sites of intramembrane di-aspartyl proteases have different consequences 
on proteolytic and signaling functions.
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 47), pp: 82006-82026
                                                     Research Paper
Oncotarget82007www.impactjournals.com/oncotarget
INTRODUCTION
Presenilins (termed PS1 and PS2 or PSEN1 and 
PSEN2 [1, 2]) are homologous di-aspartyl proteases, 
capable of cleaving various type I transmembrane proteins 
within their intramembrane domains. Mutations in PSEN1 
and PSEN2 are major causative genetic factors of familial 
cases of Alzheimer’s disease (AD), characterized by 
early onset AD manifestation [1, 2]. PSEN1 or PSEN2 
intramembranous and BACE1 extracellular cleavages 
of amyloid precursor protein (APP), produce short 40-, 
42- amino acid β-amyloid peptides (Aβ). AD autosomal 
dominant missense mutations in the presenilins have 
been reported to increase Aβ production and the ratio 
of Aβ42/40 peptides [3]. PSEN cleavage releases the 
intracellular domains (ICD) of type I proteins that can 
act as intracellular signaling molecules, activating gene 
transcription (e.g., Notch-signaling genes) (reviewed in 
[3]). Presenilins function as components of the multiple-
protein γ-secretase complex and have evolutionarily 
invariant amino acid signatures around two conserved 
catalytic aspartates and a PAL-motif (human PSEN1 - 
D257, D385, PAL433-435) (Figure 1A, Supplementary 
Figure 1) [4–11]. There are three major proteolytic 
activities associated with presenilins: (i) “presenilinase”- 
PSEN autocleavage, (ii) intramembrane γ-cleavage leading 
to generation of Aβ peptides and (iii) juxtamembrane 
ε-cleavages of APP, Notch 1 and other type I protein 
substrates resulting in release of ICDs - intracellular 
transcriptional regulators (Supplementary Figure 2) 
Active γ-secretase complex requires four proteins: 
Nicastrin, PEN2, APH1 and PSEN [12, reviewed in 13, 
14]. Although various missense mutations in PSEN1 lead 
to autosomal-dominant AD (summarized in AlzForum 
Mutation Database), heterozygous loss-of-function 
mutations in PSEN1 as well as in Nicastrin and PEN2 
(haploinsufficiency) have been shown to cause specific 
severe inflammatory skin disease, termed acne inversa in 
humans [15], reviewed in [16]. Clinical trials of drugs for 
AD inhibiting γ-secretase activity revealed various effects 
on skin, including a higher risk of skin cancer [16, 17]. In 
mice, loss of PSEN1 causes skin cancer, and a reduction 
of PSENs function is responsible for myeloproliferative 
disease [18, 19]. An inverse association between AD 
and cancer has been proposed with multiple regulatory 
mechanisms, including Pin1-, p53-, Wnt-related signaling, 
proposed to underlie the diseases [20, 21, reviewed in 22]. 
Among the important presenilin functions is regulation of 
Wnt signaling/β-catenin phosphorylation and turnover, 
which can contribute to skin cancer [18, 23–25]. This 
regulation can occur indirectly via cadherins as described 
in [26]. Another reported property of PSEN1 is its activity 
as a low conductance endoplasmic reticulum (ER) Ca2+ 
leak channel with a regulatory role in pathways linked to 
intracellular Ca2+ homeostasis [27–30]. Numerous studies 
have shown the involvement of PSEN1 in the autophagy-
lysosome degradative pathway, which is also a function 
independent of γ-secretase proteolysis [31–34]. Since both 
the up- and down-regulation of presenilins and presenilin-
mediated signaling pathways, in particular Notch, 
may lead to various cancers [18, 35–41], the balanced 
physiological level of presenilin/γ-secretase activity is 
essential for normal biological function. Therefore, the 
direct approach for down-regulation of γ-secretase by 
γ-secretase inhibitors for reduction of Aβ generation 
may not be appropriate for AD treatment. On the other 
hand, suppression or modification of proteolytic activity 
producing Aβ with retained physiological activity of 
presenilin is an attractive strategy in AD therapy.
The gene family for polytopic proteins termed 
intramembrane di-aspartyl proteases (IMPAS) or 
signal peptide proteases (SPP) includes the five known 
paralogous genes, designated as IMP1, -2, -3, -4, -5; or 
SPP, SPPL2a, -2b, -2c ,-3; or PSH gene family [42–44]. 
These proteins were described as structural homologs of 
presenilins, registered in MEROPS database as peptidase 
subfamily A22B [45]. PSEN and IMP1/SPP proteases 
share identical evolutionarily conserved motifs for the 
catalytic sites YD and GxGD and the PAL domain in their 
C-termini (Figure 1) [4-7, 42]. Unlike PSEN1 and PSEN2, 
which cleave type I transmembrane proteins, IMP1/SPP 
proteins cleave type II transmembrane substrates with 
the N-terminus oriented to the cytosol [43, 46, 47]. Some 
potent γ-secretase inhibitors can efficiently work for 
IMP1/SPP [46]. In our previous work, we showed that 
human hIMP1/SPP can cleave polytopic PSEN1 protein 
within its membrane domain in vitro [47]. In another 
independent study, a signal peptide peptidase (SPP) that 
regulates the cleavage of specific short signal peptides in 
the ER was isolated [43]. The major hIMP1 isoform is 
identical to human SPP encoded by the same gene and 
orthologous to C. elegans Ce-imp-2 gene [42, 43, 47]. 
We identified a phenotype caused by inactivation of the 
Caenorhabditis elegans hIMP1/SPP orthologue, Ce-
imp-2, possibly related to a cholesterol-dependent cellular 
pathway [48]. In vitro assays demonstrated that hIMP1/
SPP cleaves short signal peptide remnants tethered in 
ER membranes. This activity may generate short signal 
sequences that are essential for HLA-E epitopes [43, 
49]. This protease also participates in processing of the 
hepatitis C core protein (HCV core protein, [50], ER-
resident tail-anchored proteins, the unfolded protein 
response (UPR regulator XBP1u and other proteins (data 
is summarized in Supplementary Figure 3).
Modulating the different activities of PSEN and 
IMP1/SPP-related di-aspartyl intramembrane proteases 
is important for a better understanding of their functions 
and is essential for studies aimed at dissociating their 
proteolytic properties. Here we created a series of 
constructs bearing mutations focused upon (i) the highly 
conserved signature GLGD; (ii) the PAL- motif that is 
evolutionarily invariant in both the PSEN and IMP1/
SPP protein families; and (iii) AD mutation positions 
of PSEN1 (Figure 1). Various mutations in the same 
Oncotarget82008www.impactjournals.com/oncotarget
Figure 1: Structures of human presenilin 1 (PSEN1) and IMP1 (hIMP1) proteins and mutations used in the study 
(Protter program visualization, http://wlab.ethz.ch/protter).
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amino acid positions were incorporated to generate 
subtle or radical alterations of hydrophobicity of the 
sites [51–53] (Supplementary Tables 1 and 2). We tested 
how the designed mutations affect the processing and 
functional properties of PSEN1 enzyme in intramembrane 
proteolysis assays comparing to similar mutations in the 
hIMP1/SPP protease (preliminary data were reported in 
[54]). In addition, for selected mutations, we performed 
rescue experiments in a transgenic C. elegans. To test the 
effects of the mutations on non-proteolytic functions of 
PSEN1 and whether IMP1/SPP possess such functions, 
we employed ER Ca2+ leak assays using mouse embryonic 
fibroblasts deficient in the PSEN or IMP1/SPP genes.
RESULTS
Proteolytic properties of PSEN1
(1) Presenilinase auto-cleavage
Presenilin proteins undergo several post-translation 
modifications including endoproteolysis of full length 
protein (FL PSEN) by “presenilinase” within the seventh 
hydrophobic domain leading to accumulation of 27-28 
kDa N-terminal (NTF) and 16-17 kDa C-terminal (CTF) 
products [55]. “Presenilinase” is likely to be the presenilin 
per se undergoing autoprocessing in the cis-position that 
has aspartyl protease activity distinct from γ-secretase 
biochemical properties. The proteolytic event takes place 
mainly in ER compartments and requires at last one other 
γ-secretase complex component, PEN2 protein [56–60]. 
Mutations in conserved aspartates of PSEN1 are critical 
for both presenilinase and γ-secretase activities. Over-
expression of NTF or CTF fragments bearing mutations at 
catalytic aspartate sites cannot restore the γ-secretase activity 
in C. elegans mutants [61]. Mutations in the “presenilinase” 
cleavage site (PSEN1 M292D, M292E) strongly inhibit the 
autocleavage while the AD-related PSEN1ΔE9 mutation 
completely abolishes PSEN1 endoproteolysis, although 
in both cases γ-secretase remains active [59, 62]. Variable 
inhibitory effects on PSEN1 processing have been described 
for different AD-associated mutations [63–65].
We transfected PSEN1-/-/PSEN2-/- mouse embryonic 
fibroblasts (MEF) cells with wild type or mutant 
PSEN1 constructs and examined PSEN1 auto-cleavage 
products via immunoblotting using PSEN1 N-terminal 
antibody (Figure 2). We confirmed previous findings 
Figure 2: Study of PSEN1 mutants in presenilinase cleavage assay. The cleavage product was detected by PSEN1 N-terminal 
antibody. Transfections were performed in PSEN1-/-/PSEN2-/- MEF cells. Histogram shows the percent ratio of PSEN1 NTF to uncleaved 
PSEN1 holoprotein. Error bars represent SE. In this and all other Figures, mutations in super-conserved aspartates are indicated in red, 
mutations with similar amino acid changes, which do not alter the physicochemical properties of the site, are in green and AD mutations 
are in blue. P-value significance codes: ‘**’ <0.01, ‘*’ <0.05.
Oncotarget82010www.impactjournals.com/oncotarget
[4, 6] that mutations in specific aspartate residues of 
PSEN1 (D257A, D257E, D385A, D385E) completely 
abolish PSEN holoprotein cleavage as well as γ-secretase 
activity. We used cells over-expressing PSEN1 D385A 
as a dominant-negative control in all proteolytic assays. 
Our data on the effects of PSEN1 mutations indicate 
that mutations that critically change physicochemical 
properties (hydrophobicity) of the ultra-conserved amino 
acids G382, P433 and L435, strongly inhibit, but not 
completely abolish, the presenilinase activity. Similar 
amino acid substitutions G382A, P433A and L435V in 
the evolutionary conserved sites had much less or no 
effect on PSEN1 processing (Figure 2, Supplementary 
Table 1). We observed similar weak inhibitory effects of 
the various mutations in less conserved and AD-related 
amino acid positions (Figure 2). As previously described, 
AD-associated C410Y mutation led to a strong inhibition 
of PSEN1 processing (Figure 2) [64, 65].
(2) Notch1ΔE cleavage by PSEN1
Among the major PSEN substrates is a Notch 
family of proteins, which mediate important signaling 
pathways in the development and function of multicellular 
organisms [66]. PSEN1 has been shown to cleave NH2-
terminally-truncated Notch derivates (NotchΔE) within 
their intramembrane domains (ε- or S3-cleavage) and to 
release the Notch intracellular domain (NICD), which 
functions as a transcriptional activator[67–70].
We co-transfected Notch1ΔE along with different 
PSEN1 mutant constructs in PSEN1-/-/PSEN2-/- MEF cells 
and studied the cleavage products in cell-free membrane 
assays (see Material and Methods). Consistent with the 
data from the “presenilinase” cleavage assays, mutations 
in highly conserved amino acids G382, P433 and L435, 
which affect the physicochemical properties of the protein, 
completely suppress Notch1ΔE ε-cleavage, whereas 
mutations G382A, P433A and L435V had a less inhibitory 
effect (Figure 3). Among other mutations, including AD-
like mutations, only C410Y substitution abolished or 
strongly inhibited Notch1 processing (Figure 3).
(3) Production of carboxy-terminal fragments and Aβ 
peptides by APP processing
Another important type I protein proteolytically 
processed by presenilins is APP. Extramembrane 
endoproteolysis of APP by BACE produces the 99-amino 
acid C-terminus fragment anchored in the membrane. 
This C-terminus fragment is the substrate for γ-secretase 
cleavage. We used the transgenic construct APP695 
isoform (APP695ΔNL) that bears the Swedish mutation 
for AD (KM670/671NL), and enhances the overall 
production of Aβ [71–73] (Supplementary Figure 2C) 
for co-expression with the mutant PSEN1 constructs in 
PSEN1-/-/PSEN2-/-MEF cells. Mutations in PSEN genes are 
responsible for changes in intramembrane γ-proteolysis 
events, resulting in accumulation of the amyloidogenic 
product (Aβ40, Aβ42) that is the major component of 
amyloid senile plaques in AD [74–76, reviewed in 3]. 
After shedding of the extracellular N-terminal part of 
APP, cleavage in the APP ɛ-site by γ-secretase complex 
generates the carboxy-terminal amyloid intracellular 
domain (AICD) [77]. AICD, similar to NICD, can 
regulate transcription of various genes, including the genes 
encoding EGFR, a protein tyrosine kinase up-regulated in 
tumors. Reduction of PSEN1 activity can regulate EGFR-
mediated tumorogenesis [78]. PSEN1 mutants P284A/
L/Q, G382A, L435V, P433A, T440V/D, transfected into 
PSEN1-/-/PSEN2-/- MEF cells along with APP695ΔNL, 
retain their proteolytic capacity to produce AICD showing 
various inhibitory or no inhibitory effects (Figure 4). No 
APP ɛ-proteolysis products were detected when D257A/E, 
D385A/E, G382K/L/Q/V, P433L/Q PSEN1 mutants were 
transfected into the PSEN1/PSEN2 double knockout 
cells. A strong inhibitory effect on APP ɛ-cleavage was 
demonstrated for mutation in evolutionary conserved site, 
L435D, and for AD mutation C410Y (Figure 4).
For the mutations in PSEN1 highly conservative 
sites, we also analyzed the Aβ-peptide profiles. A spectrum 
of Aβ peptides were immunoprecipitated from PSEN1-/-
/PSEN2-/- MEF cells co-transfected with wild type or 
mutant PSEN1 and APP695ΔNL constructs. We showed 
that PSEN1 P433A, that retains Notch1 S3- and APP 
ɛ-cleavage activities, is also active in APP γ-site cleavage 
generating elevated level of Aβ peptides. In contrast, 
for the PSEN1 G382A that shows Notch1 S3- and APP 
ɛ-cleavage efficacy, we observed a strong inhibition of 
Aβ40 and other Aβ derivates (Figure 5). PSEN1 D385A, 
G382L, P433L mutations lead to complete inhibition of 
Aβ-peptide production compared to wild type PSEN1. 
The weak intensity low band suggesting the specific 
Aβ fragment that differs from 1-42 was also observed 
in assays for PSEN1 G382A using high-resolution 
SDS-UREA-PAGE electrophoresis. This band was not 
observed using any other mutant constructs (Figure 5, 
Supplementary Figure 4).
Proteolytic properties of IMP1/SPP
(1) Presenilin substrate cleavage
Our previous experiments, in which we co-
expressed PSEN1 holoprotein and human hIMP1/SPP 
in cultured cells, revealed that hIMP1/SPP is capable 
of cleaving a multipass transmembrane PSEN1 protein 
substrate [47]. We provided evidence that hIMP1/SPP 
may induce intramembrane proteolysis of PSEN1 in 
its last hydrophobic domain [47]. The significance of 
such cleavage activity in vivo has yet to be elucidated 
but a straightforward immunodetection assay has been 
developed to monitor proteolytic activity of IMP1 
isoforms [47].
In the present study we co-transfected different 
IMP1/SPP mutant forms with PSEN1 substrate in 
HEK293 cells. Substitution mutations to structurally 
Oncotarget82011www.impactjournals.com/oncotarget
Figure 3: Study of PSEN1 mutants in Notch1 proteolytic assay. Co-transfections of wild type or mutant PSEN1 and NotchΔE 
constructs were performed in PSEN1-/-/PSEN2-/- MEF cells. Cleavage products were detected by C-myc antibody. Histogram shows the 
percent ratio of NICD to uncleaved NotchΔE. An additional nonspecific band is marked by an asterisk. P-value significance codes: ‘*’ 
<0.05.
Figure 4: Study of PSEN1 mutants in APP ε-cleavage assay. (A, B) Co-transfections of wild type or mutant PSEN1 and APP695 
bearing the Swedish mutation (ΔNL) were performed in PSEN1-/-/PSEN2-/- MEF cells. Cell-free intramembrane cleavage was induced 
by incubation of the samples at 37°C for 2 hours. APP C99 and γ-secretase cleavage product AICD were detected by APP CTF antibody 
(Sigma). No cleavage was observed for the control samples incubated on ice (B). mAb 22C11 antibody, which detects the full-length APP 
(APP FL), was used as a transfection control in the assay (B). (C) Histogram shows the percent ratio of AICD to uncleaved APP C99. 
P-value significance codes: ‘*’ <0.05.
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similar amino acids (such as G262A, G264A, P317A 
and L319V) lead to more efficient rescue capacities than 
mutations to structurally more distant amino acids in the 
same positions of hIMP1/SPP (Figure 6, Supplementary 
Table 2). Any changes in catalytic aspartate residues 
and distant mutations in evolutionarily conserved sites 
(e.g. G262K, P317L/Q, L319D) completely or nearly 
completely inhibited the proteolysis of PSEN1 substrate. 
The G262L mutation reduced the cleavage of PSEN1 by 
approximately 40%. We have also shown that Ce-IMP-2, 
which is the C. elegans orthologue of human IMP1/SPP, 
can also cleave the C-terminal domain of human PSEN1 
with even higher efficacy than hIMP1/SPP (Figure 7 and 
below for more details).
(2) HCV substrate cleavage
We next examined how wild type and mutant 
hIMP1/SPP cleave an HCV (hepatitis C virus) 
substrate (Figure 8). hIMP1/SPP is known to cleave the 
immature form of HCV core protein in the hydrophobic 
transmembrane/C-terminal domain and this feature has 
become incorporated into a commonly used assay to 
study proteolytic properties of IMP1/SPP [50, 79]. The 
resulting cleavage product, p21 protein, along with the 
envelope proteins E1 and E2, are important structural 
components of the virus capsid [50, 80, 81]. Here we co-
transfected FLAG-tagged HCV core protein along with 
different hIMP1/SPPs and detected the cleavage products 
in HEK293 cells (Figure 8). There is a strong inhibition 
of HCV core protein cleavage by hIMP1/SPP mutations 
D265A, P317L, G262V, and to a lesser extent, by G262L 
and G262A (Figure 8). Interestingly, hIMP1 G264A and 
hIMP1 A318C demonstrated high proteolytic activity in 
the HCV cleavage assay.
Low conductance ER Ca2+leak assay
In addition to the protease function, presenilins 
may function as low conductance ion channels [27, 28]. 
Planar lipid bilayer reconstruction techniques showed 
that wild type presenilin 1 can form a Ca2+-permeable ion 
channel in the ER. Interestingly, mutations in the PSEN1 
catalytic aspartate D257A, which is essential for PSEN1 
proteolytic function, does not disrupt ion currents; whereas 
the AD mutation PSEN1 M146V impaired the channel 
function in a dominant negative manner [27]. The critical 
Figure 5: Detection of secreted Aβ peptides in cell culture medium in PSEN1-/-/PSEN2-/- MEF cells co-transfected with 
wild type or mutant PSEN1 and APP695ΔNL. Immunoprecipitation of secreted Aβ in cell conditioned medium (A, C, D) and cell 
lysates (D). Immunoprecipitated Aβ peptides were detected by 1E8 antibody. Aβ - β-amyloid ladder. M - conditioned medium, L - cell 
lysate. * - a specific Aβ peptide product, which differs from Aβ42, was detected for the G382A construct. (B) Histogram shows the relative 
ratio of total amyloid (Aβ40 and  Aβ42 or * Aβ peptide product) in PSEN1 variants calibrated to wild type Aβ40 level in 2-4 experiments. 
P-value significance codes: ‘***’ <0.001, ‘**’ <0.01. AD mutations C92S and M146V were used as positive controls for Aβ42 product.
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pore structural positions were mapped to the PSEN1 
hydrophobic domains 7 and 9 [28].
We next tested whether the mutations in glycine 
at position 382 (G382) that show variable effects on 
the proteolytic activities of PSEN1 and located in 
transmembrane domain 7 affect the cellular ER Ca2+ leak 
in PSEN1 and PSEN2 double-knockout MEFs. In a series 
of experiments, we observed that all tested mutations 
in glycine in position 382, including the G382A, which 
retains the γ-secretase activity, were unable to reconstitute 
the normal ER Ca2+leak. In contrast, PSEN1 mutants with 
substitutions in proline 433 (P433A, P433L) restore the 
Ca2+ leak function in PSEN1-/-/PSEN2-/- double-knockout 
cells similar to wild type PSEN1 function (Figure 9).
PSEN1 and IMP1/SPP are structurally related 
multipass proteins which cleave transmembrane domains 
Figure 6: Study of hIMP1 mutants proteolytic cleavage of presenilin substrate. Co-transfections of wild type or mutant 
hIMP1 and PSEN1 constructs were performed in HEK293 cells. Histogram shows the percent ratio of cleaved PSEN1 to uncleaved PSEN1 
holoprotein, detected with N-terminal hPSEN1. P-value significance codes: ‘***’ <0.001, ‘**’ <0.01, ‘*’ <0.05.
Figure 7: Ce-IMP-2 protein is efficiently cleaving hPSEN1 substrates. (A) Co-transfections of wild type C. elegans IMPAS 
and human PSEN1 constructs performed in HEK293 cells. Ce-IMP-2 protein, which is an orthologue of human IMP1, but not Ce-IMP-1 
or Ce-IMP-3, is capable of cleaving hPSEN1 holoprotein, detected with N-terminal hPSEN1 antibody. (B) Co-expression of hPSEN1 CTF 
and hIMP1 or Ce-IMP-2 protein in PSEN1-/-, PSEN2-/- double knockout fibroblasts. Efficient cleavage of hPSEN1 C-terminal fragment by 
Ce-IMP-2, with higher efficiency than by human IMP1 was detected by antibody for an N-terminal epitope of hPSEN1 CTF.
Oncotarget82014www.impactjournals.com/oncotarget
of Type I and Type II proteins with opposite orientations 
[3, 43] (Figure 1). Whether the IMP1/SPP can also 
function as Ca2+ channels has never been studied. We 
addressed this question using cultured mIMP1/SPP-/-  
MEFs obtained from mIMP1/SPP knockout mice that were 
generated in our laboratory (unpublished). We tested the 
Ca2+ flow in mIMP1/SPP-/- and wild type mIMP1/SPP+/+ 
MEF cells in comparison to PSEN1-/-/PSEN2-/- and wild 
type PSEN1+/+ MEF cells. In contrast to PSEN1 knockout 
cells, the absence of IMP1/SPP protein does not affect the 
ER Ca2+leak function, indicating that IMP1/SPP is not a 
Ca2+ pore (Figure 10).
In vivo rescue experiments in C. elegans
C. elegans is a popular and useful model organism 
for understanding the conserved mechanisms of AD-
related presenilin/γ-secretase function and in identifying 
the components of the γ-secretase and signaling pathways 
regulated by presenilins [82]. Presenilin regulation of Ca2+ 
channel activities, similar to mammals, has been recently 
demonstrated in C. elegans [30].
In the present study, we examined the in vivo effect 
of the mutation in PSEN1 (G382A) that does not suppress 
the ɛ-proteolytic activity, but inhibits the γ-secretase 
proteolytic and Ca2+ channel activities of PSEN1. We 
generated a C. elegans presenilin sel-12 gene construct 
carrying a G361A mutation that corresponds to human 
PSEN1 position G382. We tested whether this mutant gene 
construct rescues the egg-lying defect (Egl) phenotype 
of sel-12(ar171)unc-1 C. elegans mutant, which has 
a premature stop codon and inactive Sel-12/presenilin 
protein [83]. We found that sel-12 G361A, as well as sel-
12 wild type transgene expression can efficiently rescue 
the egg-lying defect (Figure 11). Li and Greenwald have 
described that reduction of the activity of another C. 
elegans presenilin homolog, hop-1, can cause lethality 
in sel-12 mutant background strains [84]. Dead embryos/
arrested larvae phenotypes are associated in general with 
a reduction of lin-12/glp-1 Notch gene function, but does 
Figure 8: HCV cleavage assay. Co-transfections of wild type or mutant hIMP1 and HCV constructs were performed in HEK293 cells. 
Histogram shows the percent ratio of cleaved HCV to uncleaved HCV core protein, detected by anti-FLAG antibody. P-value significance 
codes: ‘***’ <0.001, ‘**’ <0.01.
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not exclude the influence of other signaling pathways 
[84]. In our experiments, sel-12 G361A and sel-12 wild 
type strains, but not sur-5 GFP controls, can successfully 
survive for multiple generations being fed by hop-1 RNAi 
bacteria, proving the rescue effect of sel-12 G361A in C. 
elegans when both presenilin homologues are suppressed 
(data not shown). All together, the data demonstrate 
that ɛ-proteolytic activity, but not the Ca2+ channel leak 
function, is essential for biological functions of presenilin, 
at least in early development and Notch-signaling.
We described previously three genes in C. elegans 
(Ce-imp-1, Ce-imp-2, Ce-imp-3) that are homologous to 
five paralogous human genes (IMP1/SPP and IMP-2, -3, 
-4, -5) [42, 48]. Based on amino acid sequence alignments 
of these genes, we predicted that human hIMP1/SPP and 
Figure 9: Study of PSEN1 mutants in low conductance ER Ca2+ leak assay. The histogram shows the mean size of ionomycin 
(IO)-induced Ca2+ pool (±SD) in PSEN1-/-/PSEN2-/- MEF cells stably transfected with wild type (WT) or mutant PSEN constructs. pEGFP-C3 
plasmid was used as a negative control (NC). ‘*’ p<0.05 by ANOVA – significant Ca2+ pool changes comparing to NC. The number of cells 
analyzed is indicated (n).
Figure 10: Low conductance ER Ca2+ leak assay demonstrates that IMP1, unlike PSEN1, is not a ion channel. (A) 
Ionomycin (IO)-induced Ca2+ signal curves in PSEN1-/-/PSEN2-/-, mIMP1-/- and matching wild type control MEF lines. (B) The histogram 
presents the mean size of IO-induced Ca2+ pool (±SD) in PSEN1-/-/PSEN2-/-, mIMP1-/- and matching control MEF lines. ‘*’ p<0.05 by 
ANOVA – significant Ca2+ pool changes compared to NC. The number of cells analyzed is indicated (n).
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Ce-imp-2 are structural and functional orthologues (Figure 
1B and 12A).
In cultured cells, both human IMP1/SPP and Ce-
IMP-2 are capable of cleaving human PSEN1 holoprotein. 
Ce-IMP-2 had the high proteolytic efficiency, which is 
consistent with a functional relationship between hIMP1 
and Ce-IMP-2 orthologous proteins (Figure 7A). To 
determine whether Ce-IMP-2 is capable of cleaving a 
C-terminal PSEN1 fragment, we expressed a C-terminal 
derivative (corresponding to the PSEN1 form processed 
by “presenilinase”) with hIMP1 and Ce-IMP-2 in double 
knockout mouse PSEN1-/-/PSEN2-/- cells. The efficient 
cleavage of the C-terminus fragment was in the same 
domain and likely in an identical site that we described in 
the PSEN1 holoprotein (Figure 7B).
We reported previously that inhibition of the Ce-
imp-2 gene by microinjection of Ce-imp-2 dsRNA or 
feeding worms with E. coli, producing Ce-imp-2 dsRNA, 
resulted in slow growth, uncoordinated movement, 
reduced brood size, incomplete shedding of cuticle 
(ISC) as well as embryonic and larval death [48]. Here, 
we confirm these phenotypes in the Ce-imp-2 knockout 
strain tm1397, bearing a 536-bp deletion of the promoter, 
exon 1 and part of exon 2, and the Ce-imp-1 x Ce-imp-2 
double knockout strain tm827×tm1397 (Figure 12B). 
We analyzed the F1 progeny of Ce-imp-2+/- (tm1397) 
and Ce-imp-1-/-/Ce-imp-2+/- (tm827×tm1397) worms and 
described the phenotypes of single or double knockouts 
(Ce-imp-2-/- or Ce-imp-1-/-/Ce-imp-2-/-), confirmed by 
genotyping. The major observed phenotype was larvae 
death, about 30% of animals were able to generate eggs, 
but all the F2 progeny was inviable (Figure 12C, 12D).
We then tested the effect of mutations in the 
Ce-imp-2 gene in the rescue assays performed in the 
tm1397 Ce-imp-2 knockout strain (Figures 12, 13; 
Supplementary Figure 5). C. elegans G350A and P417A 
mutations, corresponding to human G262A and P317A, 
successfully rescued the embryonic lethality on a Ce-
imp-2-/- background (Figure 13), although the progeny 
number was overall lower compared to the Ce-imp-2 
wild type construct (Figure 13). Mutations with distant 
physicochemical properties G350K and P417L showed no 
ability to rescue the mutant phenotypes compared to Ce-
imp-2 single and Ce-imp-1 x Ce-imp-2 double knockout 
strains (Figure 14).
DISCUSSION
Uncoupling the AD-related and physiologically 
important functions of presenilins represents a promising 
approach in the search for novel strategies for AD therapy. 
Genetically inherited forms of PSENs bearing the AD 
mutations most likely do not effect the early development 
of the organism, but rather, accumulate deleterious effects 
throughout the lifetime of the individual. Less dramatic 
early effects of the mutations on CNS function and 
development, however, cannot be excluded  [85, 86]. 
Evolutionary analysis of two distantly related families of 
PSEN and IMP/SPP intramembrane di-aspartyl proteases 
shows a highly conserved amino acid signature around 
invariant aspartates in two transmembrane domains and 
the PAL motif at the C-terminal domain (Supplementary 
Figure 1). Here, we studied whether PSEN1 amino acid 
substitutions in the conserved regions of the protein 
have differential effects on PSEN1 proteolytic and 
non-proteolytic functions (Supplementary Figure 2). A 
similar mutational remodeling analysis was performed 
Figure 11: Rescue of sel-12 loss-of-function mutant phenotype in C. elegans. (A) Schematic representation of C. elegans SEL-
12 protein (human PSEN1 homolog). The Sel-12 mutant isoform was generated with the G361A mutation (analogous to human G382A) 
introduced into the conservative amino acid motif of SEL-12. The sel-12(ar171)unc-1 strain contains a W225Stop mutation that results 
in truncated protein lacking domains that are critical for SEL-12 proteolytic function. (B) Egg-laying defective (Egl) phenotype in sel- 
12(ar171)unc-1 strain. (C) The Egl phenotype is successfully rescued by injection of sel-12 wt and sel-12 G361A constructs but not by 
sur-5 GFP plasmid alone. Percentage of animals laying <15 or >15 eggs is shown. Number of analyzed animals for each strain: sel-12 wt, 
n=61; sel-12 G361A, n=51; 2 control strains: sur-5 GFP-1, n=50; sur-5 GFP-2, n=50.
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for the IMP1/SPP protein, which belongs to the family of 
evolutionarily ancient proteins distantly homologous to 
presenilins.
Previous in vivo and in vitro studies have shown 
that aspartates at positions 257 and 385 of PSEN1 play an 
essential role in γ-secretase proteolysis [4, 6, 83, 87–89]. 
These results were confirmed in our study.
The C-terminal proline 433 of PSEN1 has been 
described as being critical for γ-secretase function, 
participating in stable complex formation and catalytic 
pore structure [90-94, 28]. Our data demonstrate that 
substitutions of the conserved proline to structurally 
distant, but not to similar amino acids, suppress the 
proteolytic activity of PSEN1. However, PSEN1 with any 
mutation in this position can restore the normal Ca2+ leak 
function in PSEN1 knockout cells [28].
Mutation of the conserved leucine 435 of PSEN1 
was found in familial cases of early onset AD with the 
unusual phenotype of cotton wool plaques [95, 96]. In 
our study, substitutions to structurally distant amino acids 
in this position have a prominent inhibitory effect on 
proteolytic function of PSEN1 with complete inhibition 
of Notch1 proteolysis and a strong inhibition of APP 
ɛ-proteolysis. Presenilinase function was also inhibited by 
L435D mutation, but to a lesser extent. Another unusual 
phenotype for AD, “Lewy bodies,” is associated with 
deletion of threonine 440 [97, 98]. We have shown that 
both PSEN1 T440D and T440V support cleavage of 
various substrates.
PSEN1 with a G382A mutation in the highly 
conserved motif of the second aspartate does not change 
physiologically essential proteolytic properties of the 
Figure 12: (A) C.elegans Ce-IMP-2 protein structure and mutations studied. Functionally important super-conservative sites (D306, 
GLGD 350-353, PAL 417-419) are indicated in red. (B) The loss-of-function of Ce-imp-2 (homolog of human SPP/hIMP1) leads to two 
major defects: embryonic death and a larvae death/molting defect (black arrows) [48]. (C, D) Detailed analysis of phenotypes in progeny 
of Ce-imp-2+/- (tm1397) and Ce-imp-1-/-/Ce-imp-2+/- (tm827×tm1397) strains.
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protein. The PSEN1 G382A mutation was functionally 
active in presenilinase, Notch and APP ɛ-proteolytic 
assays. Transgenic C. elegans experiments showed a 
successful rescue of an egg-laying defect linked to Notch 
proteolysis by the G361A Sel-12 construct. Distant 
mutations G382 K/L/Q/V completely abolished Notch1 
and APP ɛ-site proteolysis and have a strong inhibitory 
effect on presenilinase cleavage. The G382 position is 
critical for supporting normal Ca2+ signaling, as none of the 
mutants at this position were able to restore normal Ca2+ 
leak function (Figure 9 and [28]). The most unexpected 
results were obtained in the Aβ peptide assay. While 
PSEN1 G382L lacks both ɛ- and γ-proteolytic activities 
and does not produce any Aβ peptides, the PSEN1 G382A 
mutant retains the ɛ-cleavage activity, but significantly 
reduces the total production of Aβ peptides. In the reported 
data the occurrence of Aβ40 and Aβ42/43 fragments was 
detected for the G382A PSEN1 mutant in HEK293 cells 
expressing APP with the Swedish mutation [99]. HEK293 
cells have a substantial endogenous PSEN1 activity [48]. 
In our study, we used a PSEN1, PSEN2 double knockout 
MEF model for expression of the mutant PSEN isoforms, 
thereby excluding any effect of endogenous PSEN activity. 
We also used a single-amino acid high resolution PAAG 
assay and noticed the minor production of a novel Aβ-
peptide form that does not correspond to Aβ40 or Aβ42. 
We demonstrated that the PSEN1 G382A mutation retains 
Notch1-proteolytic activity, which has also been described 
in [99]. However, PSEN1 G382A was reported to block 
the processing of the cell membrane glycoprotein CD44 
[99]. Nonetheless, our data revealed that Sel-12 G361A 
transgenic worms with no endogenous sel-12 presenilin 
activity are viable for multiple generations, providing 
further evidence that proteolytic activity of PSEN in 
processing of Notch is an essential biological function of 
PSEN.
Here we showed that both C. elegans Ce-IMP-2 
and human hIMP1/SPP proteins are capable of cleaving 
the same multipass transmembrane protein (PSEN1-
holoprotein and -CTF) in co-transfection experiments 
using mammalian cells (Figure 7). Interestingly, Ce-
IMP-2 induced cleavages with efficiency higher than those 
observed for hIMP1. Despite strong structural similarities, 
the Ce-IMP-2 and hIMP1 proteins have differences in 
some domains, particularly at the N-terminus. We also 
observed that human IMP1/SPP likely forms dimeric 
complexes, while the Ce-imp2 protein homolog does 
not (data not shown). Altogether, this may explain the 
difference in efficiency of cleavage of the same substrate 
between C. elegans and human IMP/SPP homologs. The 
Figure 13: Rescue of Ce-imp-2 knockout phenotype in C. elegans. The constructs producing Ce-IMP-2 wild type and several 
mutant isoforms were generated. Several independent viable transgenic strains on Ce-imp-2-/- (tm1397) background were obtained by 
picking 20-30 roller phenotype animals (pRF4 was used as a co-marker) from injected Ce-imp-2+/- worm progeny. Rescue of Ce-imp-2 
knockout phenotypes was analyzed in 40-61 animals for each transgenic Ce-imp-2-/- strain. Worms that can reach adult stage and have 
viable progeny were considered as rescued. The loss-of function Ce-imp-2 phenotype was rescued by G350A, P417A Ce-imp-2 constructs.
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data also indicate that Ce-imp-2 is a true orthologue of 
human IMP1/SPP.
We also searched available SNP databases to 
identify if any mutation in PSEN1 and hIMP1/SPP that 
we studied can be found in common human populations. 
We have not identified such SNPs in more than 2,500 
human genomes in the 1000 Genomes Project catalog 
[100]. The Ensemble variants database contains reports 
for PSEN1 AD-mutations M146V, C410Y and also 
AD-linked mutations in protein positions 284 and 
435, which differ from the mutations in this position 
described in our paper. Interestingly, the PSEN1 D257N 
somatic mutation, leading to PSEN1 haploinsufficiency, 
has been found in lung carcinoma" (Supplementary 
Table 1). Amino acid substitutions in positions 245 
and 319 of hIMP1 were found in malignant melanoma 
and endometrium carcinoma correspondingly 
(Supplementary Table 2). Thus, it would be of interest 
to elucidate further the potential role of these proteases 
in cancer.
In summary, we confirmed that any mutations 
at functionally essential aspartates of members of two 
distantly related families of intramembrane proteases, 
PSEN1 and IMP1, completely abolish all their proteolytic 
activities. Mutations in other highly conserved sites 
reduce, but do not completely suppress, at least some 
of the proteolytic activities of PSEN1. Substitutions to 
structurally distant amino-acids in the most conserved sites 
most dramatically change efficacy of proteolytic cleavages. 
Amino acid substitutions in less conserved sites (e.g. P284 
and T440 in PSEN1) can reduce substrates proteolysis, 
but to a much lesser extent. For PSEN1, among different 
proteolytic assays, “presenilinase” activity is the most 
resistant to all mutation modifications in highly conserved 
sites. The PSEN1 G382A mutant retains the functionally 
important Notch1 and APP ɛ-cleavage activities but has 
reduced APP γ-cleavage activity and does not support the 
Ca2+ leak function, but rescues the lethality of C. elegans 
Ce-imp-2 knockout. We also provided evidence that IMP1/
SPP is not a Ca2+ channel as described for the structurally 
related PSEN1.
The important finding is that a single amino acid 
alteration in transmembrane domain 7 of PSEN1 can 
reduce the AD-related intramembrane γ-secretase activity 
but retain the biologically important juxtamembrane 
proteolytic function of PSEN1. These data raise the idea 
that uncoupling AD- and biologically-essential functions 
of presenilins may represent a promising novel therapeutic 
approach.
Figure 14: No rescue of Ce-imp-2 knockout phenotypes was found by constructs producing Ce-IMP-2 G350K, P417L 
mutant proteins. If none of the 20-30 roller phenotype (transgenic marker) worms, progeny of injected Ce-imp-2+/- worms, displayed 
rescue phenotype on Ce-imp-2-/- background, then ~200 single worms, synchronized mixed viable progeny of several transgenic Ce-imp-2+/- 
animals, were analyzed. In addition, for G350K strain #1, we checked phenotypes of Ce-imp-2+/+ animals progeny. The rate of the losing 
transgenic status was estimated as percentage of non-roller wild type phenotype animals/total number of wild type phenotype animals. 
P-value significance codes: ‘**’ <0.01, ‘*’ <0.05.
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MATERIALS AND METHODS
Plasmid constructs for expression in mammalian 
cell cultures
Human IMP1 (hIMP1) and PSEN1 (hPSEN1) 
wild type constructs were described previously [47]. A 
QuikChange® Site-Directed Mutagenesis Kit (Agilent 
Technologies Inc., Santa Clara, CA, USA) was used to 
incorporate mutations in the hIMP1 and hPSEN1 genes 
(Supplementary Tables 1 and 2). PSEN1 D385A and APP 
Swedish mutant (APP695ΔNL) constructs were obtained 
from the Mayo Clinic (Mayo Clinic, Jacksonville, FL). 
mNotch1 (myc-tagged NotchΔE and NICD) constructs 
were kindly provided by Dr. R. Kopan (Washington 
University School of Medicine, St. Louis, MO, USA). 
pcDNA Flag-HCVcore-HA plasmid was a gift from 
Dr. Kohji Moriishi (Osaka University, Osaka, Japan). 
QuikChange®. pcDNA4/myc-His B or pcDNA3 plasmids 
from Invitrogen (Thermo Fisher Scientific, Waltham, MA, 
USA) were used as mock controls. cDNA clones for Ce-
imp-1, Ce-imp-2, and Ce-imp-3 genes were obtained from 
Y. Kohara (Genome Biology Lab, National Institute of 
Genetics, Mishima, Japan) and cloned into pcDNA4/myc-
His B plasmid (Invitrogen, Thermo Fisher Scientific) for 
the experiments performed in mammalian cell cultures.
Mammalian cell cultures
Knockout PSEN1-/-/PSEN2-/- and control PSEN1+/+/
PSEN2+/+ mouse embryonic fibroblasts (MEF) were 
a gift from Dr. De Strooper (Center for Human 
Genetics, Katholieke Universiteit Leuven, and Flanders 
Interuniversity Institute for Biotechnology, Leuven, 
Belgium).
HEK293 and MEF cells were cultured in DMEM 
(Gibco, Thermo Fisher Scientific) containing 10% FBS 
(Hyclone Laboratories, Logan, UT), 2 mM L-glutamine 
at 37°C and 1% penicillin/streptomycin, 5% CO2. Primary 
cultures of MEF were generated from 13.5 dpc hIMP1 
knockout embryos and immortalized by continuous 
passaging (unpublished). 
Transfection of mammalian cell lines and 
immunoblotting
Transient transfections were performed using 
Lipofectamine Plus Reagent (Invitrogen, Thermo 
Fisher Scientific) according to the manufacturer’s 
instructions. After 24-48 hours of transfection, cells were 
briefly washed 2 times in cold PBS, lysed in modified 
RIPA-buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 
0.25% deoxcholate Na, 150 mM NaCl, 1 mM EDTA) 
supplemented with Complete Mini Protease Inhibitor 
Cocktail (Roche Diagnostics, Indianapolis, IN) for 15 min 
at 4°C and subsequently centrifuged at 14,000 rpm for 
10 min at 4°C. A NOVEX mini-cell gel electrophoresis 
system (Invitrogen, Thermo Fisher Scientific) was used 
for protein separation and electrotransfer procedures. Cell 
lysates (10-20 μg of total protein) or 10 μl of conditioned 
culture medium were mixed with 5x Laemmli sample 
buffer with reducing agent (1x sample buffer composition: 
60 mM Tris-Cl pH 6.8, 2% SDS, 10% glycerol, 5 % 
β-mercaptoethanol, 0.01% bromophenol blue) centrifuged 
at 12,000 rpm for 5 min with or without prior boiling for 
5 min, and loaded onto SDS PAAG mini-gels (Invitrogen, 
Thermo Fisher Scientific). Prestained molecular weight 
markers (Invitrogen, Thermo Fisher Scientific) were 
loaded into a separate well. Electrophoresis was run either 
in 10% (PSEN1, HCV detection) or 8% (Notch detection) 
Tris-Glycine PAAG or in Novex® 10-20% Tricine Gel 
(for APP-CT detection) in 1X SDS running buffer at 125 
V. After electrotransfer, Immobilon-P PVDF membranes 
(EMD Millipore, Billerica, MA USA) were washed in 
TBS-T buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
0.05% Tween 20) 1 time for 10 min and 3 times for 5 
min, incubated in blocking buffer (5% milk in TBS-T) 
at room temperature for 1 hour and placed in 10 ml of 
hybridization buffer (1% milk in TBS-T), containing 
primary antibodies in 1:500 – 1:5000 dilution, at 4°C 
overnight. After incubation with appropriate secondary 
antibodies, signal visualization was performed using an 
ECL Western blotting detection reagent kit and exposure 
to an X-ray film or via image capturing using a VersaDoc 
5000 imaging system (Bio-Rad Laboratories, Hercules, 
CA). Experiments were replicated multiple times ( ≥3).
Polyclonal rabbit antibodies against hPSEN1 
N-terminal polypeptide and CTF were described 
previously [47]. Antibody against c-myc epitope for 
IMP1 and Notch detection was obtained from Invitrogen 
(Thermo Fisher Scientific). The released APP intracellular 
fragments were detected in supernatants using polyclonal 
APP CTF antibody (Sigma-Aldrich). For detection of Aβ 
peptides, mAb 1E8 (Bayer-Schering Pharma AG, Berlin, 
Germany or provided by T. Dyrks, Schering, Berline, 
Germany) was used while mAb 22C11 was used for 
detection of N-terminal APP fragments (Chemicon, EMD 
Millipore). For HCV detection, monoclonal mouse anti-
FLAG (Sigma-Aldrich) was used.
Cell-free intramembrane cleavage assay
For intramembrane cleavage assays, PSEN1-/-/PSEN2-/- 
MEF cells were transfected with either APP695ΔNL or 
NotchΔE and one of the PSEN1 isoforms or mock plasmid. 
After 48 hours of transfection, cells were washed twice with 
ice-cold PBS, scraped off the dishes, resuspended in 0.5 ml 
of hypotonic homogenization buffer (10 mM HEPES, pH 
7.2; protease inhibitors cocktail), incubated on ice for 1 hour 
and frozen in liquid nitrogen. Frozen cells were thawed 
on ice for 1 hour and homogenized by passing through a 
22-gauge hypodermic needle 5 times. Homogenates were 
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centrifuged at 1000 at 4°C for 10 min and post-nuclear 
supernatants were saved. To isolate crude membranes, post-
nuclear supernatants were subjected to centrifugation at 
20000 g, 4°C for 45 min and the pellets were resuspended in 
assay buffer (150 mM Sodium Citrate, pH 6.4, 5 mM EDTA, 
protease inhibitors cocktail). Intramembrane cleavage was 
induced by incubation of the samples at 37°C for 2 hours. 
Reactions were stopped by placing samples on ice, and 
membranes precipitated by centrifugation at 16000 g, 4°C 
for 30 min. The released cleavage fragments were detected 
in supernatants and analyzed by immunoblot.
Immunoprecipitation of Aβ secreted in cell 
culture media
After 24 hours of transfection, plates were washed 
twice with 1×DPBS and incubated for 24 hours in 
serum-free O-MEM. Conditioned media were collected, 
centrifuged at 3000 g for 10 min and supernatants were 
subjected to immunoprecipitation as described in [101]. 
Briefly, 400 μl of medium were mixed with 100 μl of 
5x RIPA buffer (2.5% IGEPAL CA-630, 1.25% sodium 
deoxycholate, 0.25% SDS, 750 mM NaCl, 250 mM 
HEPES, pH 7.4) supplemented with 1 tablet of Complete 
Mini Protease Inhibitor Cocktail per 2 ml of 5x RIPA. 
Magnetic beads (25 μl; DynaBeads, Thermo Fisher 
Scientific) coupled with monoclonal antibody 1E8 (1 μg of 
mAb 1E8 per 1.68 × 107 beads) per reaction were added. 
Samples were incubated on a shaker at 4°C overnight. 
After washing in PBS, 0.1% BSA three times and one time 
in 10 mM Tris-HCl, pH 7.4, Aβ peptides were eluted from 
the magnetic beads in sample buffer containing 0.36 M 
bis-Tris, 0.16 M N, N'-bis-(2-hydroxyethyl)-glycine, 1% 
SDS, 15% sucrose, and 0.004% bromophenol blue, 2.5% 
DTT at 95°C for 5 min.
SDS-PAGE of Aβ peptides
Aβ peptides were separated in 0.5 mm thick 
13% T%/5% C/8M urea bicine/bis-Tris/Tris SDS-
PAGE minigels, (T%-total percentage concentration 
of acrylamide monomer, C% - the percentage of 
crosslinker relative to the total acrylamide monomer) 
[101]. Electrophoresis was for 2 hours at a constant 
current of 12 mA per gel at ambient temperature. Aβ 
peptides were transferred onto Immobilon-P PVDF 
membranes (Millipore, Billerica, MA USA) using a TE-
70 ECL Semi-Dry Transfer Unit (GE Healthcare Life 
Sciences, Piscataway Township, NJ, USA) for 30 min 
at 1 mA/cm2 at room temperature as described in [102]. 
After transfer was completed, membranes were briefly 
washed in deionized water, boiled in 1 × PBS for 3 min 
in a microwave, blocked in Roti-Block blocking buffer 
(Carl Roth GmbH, Karlsruhe, Germany) and incubated 
with primary mAb 1E8 diluted 1:300 overnight at 4°C. 
After a series of washes in PBS-T buffer (1×PBS, 0.075% 
Tween 20), membranes were incubated with secondary 
anti-mouse horse radish peroxidase-conjugated antibody 
(Pierce Biotechnology, Thermo Fisher Scientific) 1:5000 
for 1 h at room temperature, washed 3 x 10 min in PBS-T 
and subsequently developed for 5 min with ECL Advance 
reagents (GE Healthcare Life Sciences). Signals were 
detected using a VersaDock 5000 MP Imaging System, 
and analyzed using Quantity One 4.6.3 software (Bio-
Rad Laboratories, Hercules, CA, USA). Along with 
bicine/bis-Tris/Tris SDS-PAGE, 10 μl of each sample of 
conditioned medium were analyzed by Tris-glycine PAAG 
electrophoresis-immunoblot with monoclonal 22C11 
antibody, that recognizes full length APP. To normalize 
signals of Aβ peptides, serial dilutions of synthetic Aβ 
peptides (Aβ 1-37, Aβ 1-38, Aβ 1-39, Aβ 1-40, Aβ 1-42, 
Aβ 2-42, Bachem, Bubendorf, Switzerland) were used 
[103].
C. elegans experiments
Standard methods of C. elegans handling and culture 
were applied [104]. N2 Bristol strain was used as the 
wild type. Sel-12(ar171)unc-1 (e538) was provided by I. 
Greenwald (Columbia University, New York, USA). Tm827 
(Ce-imp-1 knockout), tm1397 (Ce-imp-2 knockout) and 
tm1654 (Ce-imp-3 knockout) were provided by the Mitani 
Laboratory, Tokyo Women's Medical University School of 
Medicine, Japan and outcrossed 3-5 times to the N2 strain. 
A C. elegans ~6 kb sel-12 genomic fragment containing 
~3 kb of the 5'- and ~0.8 kb of the 3'- regulatory regions 
were cloned into the L4440 vector. Ce-imp-2 constructs 
are described in Supplementary Figure 5. Mutations in 
the sel-12 and Ce-imp-2 genes were introduced using a 
QuikChange® Site-Directed Mutagenesis Kit (Stratagene, 
Agilent Technologies). RNA interference (RNAi) by 
dsRNA feeding and germ-line injections were performed 
as previously described [48]. Sur-5 GFP or pRF4 
plasmids were used as germ-line co-injection markers. 
Ce-imp knockout and transgenic strains were genotyped 
accordingly (Supplementary Figure 5, Supplementary Table 
3). The progeny of the heterozygous deletion mutant Ce-
imp-2 were analyzed by single worm PCR.
ER Ca2+ channel leak study
Experimental methodology for measuring ER Ca2+ 
channel leak was previously described [27, 28].
Statistical analysis
Plotted values represent mean ± standard error of 
the mean. Comparisons of more than two groups were 
carried out using one-way ANOVA and unpaired T-test 
against WT values as the control group (Figure 2-4, 6, 
8). For the analysis of total Aβ in PSEN1 mutants (Figure 
5) and C. elegans experiments (Figure 13-14) WT values 
were converted to Z-score using mutant data and two-
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tailed P-value was calculated. In all cases P < 0.05 was 
considered to be statistically significant after adjusting for 
multiple testing with Benjamini & Hochberg procedure.
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